Medical Device User Fee Rates for Fiscal Year 2007, 43784-43786 [E6-12394]
Download as PDF
43784
Federal Register / Vol. 71, No. 148 / Wednesday, August 2, 2006 / Notices
TABLE 4.
FEE CATEGORY
FEE RATES FOR FY 2007
APPLICATIONS
Requiring clinical data ............................................................................................................................................
Not requiring clinical data ......................................................................................................................................
Supplements requiring clinical data .......................................................................................................................
ESTABLISHMENTS ...................................................................................................................................................
PRODUCTS ...............................................................................................................................................................
VIII. Implementation of Adjusted Fee
Schedule
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
A. Application Fees
Food and Drug Administration
The appropriate application fee
established in the new fee schedule
must be paid for any application or
supplement subject to fees under
PDUFA that is received after September
30, 2006. Payment must be made in U.S.
currency by check, bank draft, or U.S.
postal money order payable to the order
of the Food and Drug Administration.
Please include the user fee ID number
on your check. Your payment can be
mailed to: Food and Drug
Administration, P.O. Box 360909,
Mellon Client Service Center, 500 Ross
St., rm. 670, Pittsburgh, PA 15251–6909.
If checks are to be sent by a courier
that requests a street address, the
courier can deliver the checks to: Food
and Drug Administration (360909),
Mellon Client Service Center, 500 Ross
St., rm. 670, Pittsburgh, PA 15262–0001.
(Note: This Mellon Bank address is for
courier delivery only.)
Please make sure that the FDA post
office box number (P.O. Box 360909) is
written on the check. The tax
identification number of the Food and
Drug Administration is 530 19 6965.
Medical Device User Fee Rates for
Fiscal Year 2007
B. Establishment and Product Fees
By August 31, 2006, FDA will issue
invoices for establishment and product
fees for FY 2007 under the new fee
schedule. Payment will be due on
October 1, 2006. FDA will issue
invoices in October 2007 for any
products and establishments subject to
fees for FY 2007 that qualify for fees
after the August 2006 billing.
wwhite on PROD1PC61 with NOTICES
Dated: July 26, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–12397 Filed 8–1–06; 8:45 am]
BILLING CODE 4160–01–S
VerDate Aug<31>2005
16:40 Aug 01, 2006
Jkt 208001
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is publishing the
fee rates and payment procedures for
medical device user fees for fiscal year
(FY) 2007. The Federal Food, Drug, and
Cosmetic Act (the act), as amended by
the Medical Device User Fee and
Modernization Act of 2002 (MDUFMA)
and the Medical Device User Fee
Stabilization Act of 2005 (MDUFSA),
authorizes FDA to collect user fees for
certain medical device applications. The
FY 2007 fee rates are provided in this
notice. For all applications submitted on
or after October 1, 2006, and through
September 30, 2007, fees must be paid
at the FY 2007 rates at the time the
applications are submitted to FDA. The
fee you must pay is the fee that is in
effect on the later of the date that your
application is received by FDA or the
date your check is received. This notice
provides details on how fees for FY
2007 were determined and payment
procedures for medical device
applications subject to user fees.
FOR FURTHER INFORMATION CONTACT: For
further information on MDUFMA: Visit
the FDA Web site https://www.fda.gov/
cdrh/mdufma.
For questions relating to this notice:
Frank Claunts, Office of Management
(HF–20), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4427.
SUPPLEMENTARY INFORMATION:
I. Background
Section 738 of the act (21 U.S.C. 379
j) establishes fees for certain medical
device applications and supplements.
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
$896,200
$448,100
$448,100
$313,100
$49,750
Under statutorily defined conditions,
FDA may waive or reduce fees (21
U.S.C. 379j(d) and (e)).
Under MDUFMA, the fee rate for each
type of application is set at a specified
percentage of the standard fee for a
premarket application (a premarket
application is a premarket approval
application (PMA), a product
development protocol, or a biologic
licensing application). MDUFSA
specifies that the standard fee for a
premarket application submitted during
FY 2007 is $281,600. From this starting
point, this notice establishes fee rates
for FY 2007. These fees are effective on
October 1, 2006, and will remain in
effect through September 30, 2007.
II. Fee Calculations for FY 2007
Under the act, all fees are set as a
percent of the full fee for a premarket
application (see 21 U.S.C. 379j(a)(1)(A)),
and the act sets the standard fee for a
premarket application at $281,600 for
FY 2007 (see 21 U.S.C. 379j(c)(1); this is
referred to as the ‘‘base fee.’’ A 180-day
supplement is set at 21.5 percent of the
base fee; the fee for a real-time
supplement is set at 7.2 percent of the
base fee (see 21 U.S.C. 379j(a)(1)(A)).
For all applications other than
premarket notification submissions
(510(k)s), the small business rate is 38
percent of the standard (full fee) rate
(see 21 U.S.C. 379j(d)(2)(C)). For 510(k)
premarket notification submissions, the
fees are to be set so that fees from all
510(k)s would produce revenue as if all
were assessed a fee of 1.42 percent of
the base fee, but these fee rates are to be
adjusted so that the fee paid by a
qualifying small business is 80 percent
of the full rate for a 510(k) premarket
notification submission (see 21 U.S.C.
379j(e)(2)(C)). Based on FDA’s estimates,
about 19 percent of 510(k) premarket
notifications will qualify for the small
business fee, and about 81 percent will
pay the standard (full) fee. The FY 2007
fee rates for all application categories
are set out in table 1 of this document.
E:\FR\FM\02AUN1.SGM
02AUN1
Federal Register / Vol. 71, No. 148 / Wednesday, August 2, 2006 / Notices
43785
TABLE 1.—FEE TYPES, PERCENT OF PMA FEE, AND FY 2007 FEE RATES
Full Fee Amount
as a Percent of
Premarket Application Fee
Application Fee Type
FY 2007 Full Fee
PMA (submitted under section 515(c)(1) or 515(f)
of the act or section 351 of the Public Health Service (PHS) Act)
FY 2007 Small
Business Fee
$281,600
$107,008
Premarket Report (submitted under section 515(c)(2) of the act)
100%
$281,600
$107,008
Panel Track Supplement
100%
$281,600
$107,008
Efficacy Supplement (to an approved premarket
application under section
351 of the PHS Act)
100%
$281,600
$107,008
180-Day Supplement
21.5%
$60,544
$23,007
7.2%
$20,275
$7,705
1.42% in
aggregate
$4,158
$3,326
Real Time Supplement
wwhite on PROD1PC61 with NOTICES
510(k)
III. Small Business Qualification for
Purposes of MDUFMA Fees
Firms with annual gross sales or
receipts of $30 million or less, including
the gross sales and receipts of all
affiliates, partners, and parent firms,
may qualify for a fee waiver for their
first PMA. Firms with annual gross sales
or receipts of $100 million or less,
including the gross sales and receipts of
all affiliates, partners, and parent firms,
may qualify for lower rates for all
applications that are subject to a fee.
Even if a firm qualified under the act
as a small business for MDUFMA fees
in FY 2006, it must obtain a new small
business certification and decision
number for FY 2007 and for each
subsequent FY. This can be initiated
any time after the publication of this
notice. A firm that does not have an FY
2007 small business qualification
decision number from FDA will not be
permitted to submit the reduced small
business fees for applications submitted
during FY 2007. FDA urges firms to
apply for this qualification at least 60
days before they intend to submit their
application and fee.
To qualify, you are required to submit
the following:
(1) A completed FY 2007 Small
Business Qualification Certification
(Form FDA 3602). This form is provided
in FDA’s guidance document, FY 2007
MDUFMA Small Business Qualification
Worksheet and Certification, available
on FDA’s Web site at https://
www.fda.gov/cdrh/mdufma. This form
is not available separate from the
guidance document.
(2) Certified copies of your Federal
(U.S.) Income Tax Return for the most
recent taxable year (2005 or later), and
certified copies of the income tax
VerDate Aug<31>2005
16:40 Aug 01, 2006
Jkt 208001
returns of your affiliates, partners and
parent firms.You can find information
for determining if an applicant qualifies
for a small business first-time PMA
waiver and lower rates for subsequent
applications on the FDA Web site at
https://www.fda.gov/cdrh/mdufma. At
that Web site, under the heading
‘‘Guidance Documents,’’ click on the
link ‘‘Qualifying as a Small Business.’’
This Web site provides detailed
instructions and the address for mailing
documentation to support qualification
as a small business under MDUFMA.
IV. Procedures for Paying Application
Fees
Any application or supplement
subject to fees under MDUFMA that is
received on or after October 1, 2006,
through September 30, 2007, is subject
to the FY 2007 fee rate. The later of the
date that the application is received in
the reviewing center’s document room
or the date that the check is received by
US Bank determines whether the fee
rates for FY 2006 or FY 2007 apply.
FDA must receive the correct fee at the
time that an application is submitted, or
the application will not be accepted for
filing or review.
FDA requests that you follow the
steps below before submitting a medical
device application subject to a fee.
Please pay close attention to these
procedures to ensure that FDA links the
fee with the correct application. (Note:
In no case should the check for the fee
be submitted to FDA with the
application.)
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
A. Step One—Secure a Payment
Identification Number and Medical
Device User Fee Cover Sheet From FDA
Before Submitting Either the
Application or the Payment. Note: FY
2007 fee rates will be available on the
Cover Sheet Web Site beginning on
September 5, 2007
Log onto the MDUFMA Web site at
https://www.fda.gov/oc/mdufma and,
under the forms heading, click on the
link ‘‘User Fee Cover Sheet.’’ Complete
the Medical Device User Fee Cover
Sheet. Be sure you choose the correct
application submission date range. (Two
choices will be offered from September
5 until October 1, 2006. One choice is
for applications that will be received on
or before September 30, 2006, which
will be subject to FY 2006 fee rates. A
second choice is for applications that
will be received on or after October 1,
2006, which will be subject to FY 2007
fee rates.) After completing data entry,
print a copy of the Medical Device User
Fee Cover Sheet and note the unique
Payment Identification Number located
in the upper right-hand corner of the
printed cover sheet.
B. Step Two—Electronically Transmit a
Copy of the Printed Cover Sheet with the
Payment Identification Number to
FDA’s Office of Financial Management
Once you are satisfied that the data on
the cover sheet is accurate,
electronically transmit that data to FDA
according to instructions on the screen.
Since electronic transmission is
possible, applicants are required to set
up a user account and use passwords to
assure data security in the creation and
electronic submission of cover sheets.
E:\FR\FM\02AUN1.SGM
02AUN1
43786
Federal Register / Vol. 71, No. 148 / Wednesday, August 2, 2006 / Notices
C. Step Three—Mail Payment and a
Copy of the Completed Medical Device
User Fee Cover Sheet to the St. Louis
Address Specified Below
Dated: July 26, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–12394 Filed 8–1–06; 8:45 am]
• Make the payment in U.S. currency
by check, bank draft, or U.S. Postal
money order payable to the Food and
Drug Administration. (The tax
identification number of the Food and
Drug Administration is 53–0196965,
should your accounting department
need this information.)
• Please write your application’s
unique Payment Identification Number,
from the upper right-hand corner of
your completed Medical Device User
Fee Cover Sheet, on your check, bank
draft, or U.S. Postal money order.
• Mail the payment and a copy of the
completed Medical Device User Fee
Cover Sheet to: Food and Drug
Administration, P.O. Box 956733, St.
Louis, MO, 63195–6733.
If you prefer to send a check by a
courier (such as FEDEX, DHL, UPS,
etc.), the courier may deliver the check
to: US Bank, Attn: Government Lockbox
956733, 1005 Convention Plaza, St.
Louis, Missouri 63101.
(Note: This address is for courier
delivery only. Contact the US Bank at
314–418–4821 if you have any questions
concerning courier delivery.)
It is helpful if the fee arrives at the
bank at least 1 day before the
application arrives at FDA. FDA records
the official application receipt date as
the later of the following:
• The date the application was
received by FDA.
• The date US Bank receives the
payment. US Bank is required to notify
FDA within 1 working day, using the
Payment Identification Number
described previously.
BILLING CODE 4160–01–S
wwhite on PROD1PC61 with NOTICES
D. Step Four—Submit your Application
to FDA with a Copy of the Completed
Medical Device User Fee Cover Sheet
Please submit your application and a
copy of the completed Medical Device
User Fee Cover Sheet to one of the
following addresses:
• Medical device applications should
be submitted to: Food and Drug
Administration, Center for Devices and
Radiological Health, Document Mail
Center (HFZ–401), 9200 Corporate
Blvd., Rockville, MD 20850.
• Biologic applications should be sent
to: Food and Drug Administration,
Center for Biologics Evaluation and
Research, Document Control Center
(HFM–99), suite 200N, 1401 Rockville
Pike, Rockville, Maryland 20852–1448.
VerDate Aug<31>2005
16:40 Aug 01, 2006
Jkt 208001
DEPARTMENT OF HOMELAND
SECURITY
Proposed Action
Coast Guard
[CGD13–06–034]
Announcement of Public Hearing
Regarding the Interstate 5 Bridge
Replacement Project Across the
Columbia River Between Portland, OR
and Vancouver, WA
Coast Guard, DHS.
Notice of public hearing.
AGENCY:
ACTION:
SUMMARY: The Coast Guard will hold a
public hearing to receive comments on
the Interstate 5 Bridge Replacement
Project, also known as the Columbia
River Crossing Project, between
Portland, Oregon and Vancouver,
Washington. The dual vertical lift
highway bridges across the Columbia
River, mile 106.5, are being examined as
candidates for replacement. Comments
regarding impacts that the proposed
bridge replacement project may have on
navigation of the Columbia River and
the environment will be of particular
relevance to the Coast Guard’s bridge
permitting responsibilities.
DATES: This hearing will be held on
Thursday, September 21, 2006, from 6
p.m. to 9 p.m., or later if necessary.
Attendees at the hearing who wish to
present testimony and have not
previously made a request to do so, will
follow those having submitted a request,
as time permits. Written material and
requests to make oral comment must be
received by the Bridge Administrator at
the address given under ADDRESSES on
or before September 14, 2006.
ADDRESSES: The hearing will be held at
the Red Lion Hotel on the River—
Jantzen Beach, 909 North Hayden Drive,
Portland, Oregon. The Timberline Room
downstairs from the main lobby has
been reserved. Send written material
and requests to make oral comment to
Mr. Austin Pratt, Bridge Administrator,
Commander (dpw), Thirteenth Coast
Guard District, 915 Second Avenue,
Room 3510, Seattle, WA 98174–1067.
Commander (dpw) maintains the
public docket and comments and
material received from the public will
become part of docket [CGD13–06–034]
and will be available for inspection or
copying at the above address between 8
PO 00000
Frm 00077
a.m. and 4:30 p.m., Monday through
Friday, except Federal holidays.
FOR FURTHER INFORMATION CONTACT: If
you have questions regarding this notice
or the proposed project, call Mr. Austin
Pratt, Thirteenth Coast Guard District,
Bridge Administrator, telephone (206)
220–7282.
SUPPLEMENTARY INFORMATION:
Fmt 4703
Sfmt 4703
The Interstate 5 Bridge Replacement
Project under consideration will
improve the mobility, reliability, and
accessibility for automobile, freight,
transit, bicycle, and pedestrian users of
the Interstate 5 corridor from State
Route 500 in Vancouver to Columbia
Boulevard in Portland while meeting
the reasonable needs of navigation. The
existing Interstate 5 dual vertical lift
highway bridges currently provide a 40foot vertical clearance in the closed
position. When raised, the lift spans
increase the vertical clearance to 178.9
feet. Critical issues include the
determination of the vertical clearance
in a fixed span alternative as well as
pier placement in the river. In addition
to current navigational interests,
existing conditions potentially
impacting navigational clearances
include the surrounding land uses, the
Burlington Northern-Santa Fe rail line
bridge (approximately one mile
downstream), and the glide path
requirements for Pearson Airpark in
Vancouver and Portland International
Airport in Portland. While the main
focus of the hearing is to allow
interested persons to present comments
and information concerning the impact
of the proposed bridge project on
navigation and air space, comments
concerning impacts on the human
environment may also be presented and
will be included in the public record.
The Federal Highway Administration
and Federal Transit Administration are
the joint lead Federal agencies for
satisfying the requirements of Section
102(2) of the National Environmental
Policy Act of 1969 (NEPA), and the
preparation of a Draft Environmental
Impact Statement (DEIS) has
commenced. The Coast Guard is a
cooperating agency. This replacement
bridge project will require a bridge
permit from the Coast Guard (33 U.S.C.
525) and environmental review
pursuant to NEPA.
Procedural
All interested parties will have an
opportunity to be heard and to present
evidence regarding the impacts of the
proposed bridge project. Written
statements and other exhibits in lieu of,
E:\FR\FM\02AUN1.SGM
02AUN1
Agencies
[Federal Register Volume 71, Number 148 (Wednesday, August 2, 2006)]
[Notices]
[Pages 43784-43786]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12394]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Medical Device User Fee Rates for Fiscal Year 2007
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is publishing the fee
rates and payment procedures for medical device user fees for fiscal
year (FY) 2007. The Federal Food, Drug, and Cosmetic Act (the act), as
amended by the Medical Device User Fee and Modernization Act of 2002
(MDUFMA) and the Medical Device User Fee Stabilization Act of 2005
(MDUFSA), authorizes FDA to collect user fees for certain medical
device applications. The FY 2007 fee rates are provided in this notice.
For all applications submitted on or after October 1, 2006, and through
September 30, 2007, fees must be paid at the FY 2007 rates at the time
the applications are submitted to FDA. The fee you must pay is the fee
that is in effect on the later of the date that your application is
received by FDA or the date your check is received. This notice
provides details on how fees for FY 2007 were determined and payment
procedures for medical device applications subject to user fees.
FOR FURTHER INFORMATION CONTACT: For further information on MDUFMA:
Visit the FDA Web site https://www.fda.gov/cdrh/mdufma.
For questions relating to this notice: Frank Claunts, Office of
Management (HF-20), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-4427.
SUPPLEMENTARY INFORMATION:
I. Background
Section 738 of the act (21 U.S.C. 379 j) establishes fees for
certain medical device applications and supplements. Under statutorily
defined conditions, FDA may waive or reduce fees (21 U.S.C. 379j(d) and
(e)).
Under MDUFMA, the fee rate for each type of application is set at a
specified percentage of the standard fee for a premarket application (a
premarket application is a premarket approval application (PMA), a
product development protocol, or a biologic licensing application).
MDUFSA specifies that the standard fee for a premarket application
submitted during FY 2007 is $281,600. From this starting point, this
notice establishes fee rates for FY 2007. These fees are effective on
October 1, 2006, and will remain in effect through September 30, 2007.
II. Fee Calculations for FY 2007
Under the act, all fees are set as a percent of the full fee for a
premarket application (see 21 U.S.C. 379j(a)(1)(A)), and the act sets
the standard fee for a premarket application at $281,600 for FY 2007
(see 21 U.S.C. 379j(c)(1); this is referred to as the ``base fee.'' A
180-day supplement is set at 21.5 percent of the base fee; the fee for
a real-time supplement is set at 7.2 percent of the base fee (see 21
U.S.C. 379j(a)(1)(A)).
For all applications other than premarket notification submissions
(510(k)s), the small business rate is 38 percent of the standard (full
fee) rate (see 21 U.S.C. 379j(d)(2)(C)). For 510(k) premarket
notification submissions, the fees are to be set so that fees from all
510(k)s would produce revenue as if all were assessed a fee of 1.42
percent of the base fee, but these fee rates are to be adjusted so that
the fee paid by a qualifying small business is 80 percent of the full
rate for a 510(k) premarket notification submission (see 21 U.S.C.
379j(e)(2)(C)). Based on FDA's estimates, about 19 percent of 510(k)
premarket notifications will qualify for the small business fee, and
about 81 percent will pay the standard (full) fee. The FY 2007 fee
rates for all application categories are set out in table 1 of this
document.
[[Page 43785]]
Table 1.--Fee Types, Percent of PMA Fee, and FY 2007 Fee Rates
----------------------------------------------------------------------------------------------------------------
Full Fee Amount
as a Percent of FY 2007 Small
Application Fee Type Premarket FY 2007 Full Fee Business Fee
Application Fee
----------------------------------------------------------------------------------------------------------------
PMA (submitted under section 515(c)(1) or 515(f) ................. $281,600 $107,008
of the act or section 351 of the Public Health Service
(PHS) Act)
----------------------------------------------------------------------------------------------------------------
Premarket Report (submitted under section 515(c)(2) of 100% $281,600 $107,008
the act)
----------------------------------------------------------------------------------------------------------------
Panel Track Supplement 100% $281,600 $107,008
----------------------------------------------------------------------------------------------------------------
Efficacy Supplement (to an approved premarket 100% $281,600 $107,008
application under section
351 of the PHS Act)
----------------------------------------------------------------------------------------------------------------
180-Day Supplement 21.5% $60,544 $23,007
----------------------------------------------------------------------------------------------------------------
Real Time Supplement 7.2% $20,275 $7,705
----------------------------------------------------------------------------------------------------------------
510(k) 1.42% in $4,158 $3,326
aggregate
----------------------------------------------------------------------------------------------------------------
III. Small Business Qualification for Purposes of MDUFMA Fees
Firms with annual gross sales or receipts of $30 million or less,
including the gross sales and receipts of all affiliates, partners, and
parent firms, may qualify for a fee waiver for their first PMA. Firms
with annual gross sales or receipts of $100 million or less, including
the gross sales and receipts of all affiliates, partners, and parent
firms, may qualify for lower rates for all applications that are
subject to a fee.
Even if a firm qualified under the act as a small business for
MDUFMA fees in FY 2006, it must obtain a new small business
certification and decision number for FY 2007 and for each subsequent
FY. This can be initiated any time after the publication of this
notice. A firm that does not have an FY 2007 small business
qualification decision number from FDA will not be permitted to submit
the reduced small business fees for applications submitted during FY
2007. FDA urges firms to apply for this qualification at least 60 days
before they intend to submit their application and fee.
To qualify, you are required to submit the following:
(1) A completed FY 2007 Small Business Qualification Certification
(Form FDA 3602). This form is provided in FDA's guidance document, FY
2007 MDUFMA Small Business Qualification Worksheet and Certification,
available on FDA's Web site at https://www.fda.gov/cdrh/mdufma. This
form is not available separate from the guidance document.
(2) Certified copies of your Federal (U.S.) Income Tax Return for
the most recent taxable year (2005 or later), and certified copies of
the income tax returns of your affiliates, partners and parent
firms.You can find information for determining if an applicant
qualifies for a small business first-time PMA waiver and lower rates
for subsequent applications on the FDA Web site at https://www.fda.gov/
cdrh/mdufma. At that Web site, under the heading ``Guidance
Documents,'' click on the link ``Qualifying as a Small Business.'' This
Web site provides detailed instructions and the address for mailing
documentation to support qualification as a small business under
MDUFMA.
IV. Procedures for Paying Application Fees
Any application or supplement subject to fees under MDUFMA that is
received on or after October 1, 2006, through September 30, 2007, is
subject to the FY 2007 fee rate. The later of the date that the
application is received in the reviewing center's document room or the
date that the check is received by US Bank determines whether the fee
rates for FY 2006 or FY 2007 apply. FDA must receive the correct fee at
the time that an application is submitted, or the application will not
be accepted for filing or review.
FDA requests that you follow the steps below before submitting a
medical device application subject to a fee. Please pay close attention
to these procedures to ensure that FDA links the fee with the correct
application. (Note: In no case should the check for the fee be
submitted to FDA with the application.)
A. Step One--Secure a Payment Identification Number and Medical Device
User Fee Cover Sheet From FDA Before Submitting Either the Application
or the Payment. Note: FY 2007 fee rates will be available on the Cover
Sheet Web Site beginning on September 5, 2007
Log onto the MDUFMA Web site at https://www.fda.gov/oc/mdufma and,
under the forms heading, click on the link ``User Fee Cover Sheet.''
Complete the Medical Device User Fee Cover Sheet. Be sure you choose
the correct application submission date range. (Two choices will be
offered from September 5 until October 1, 2006. One choice is for
applications that will be received on or before September 30, 2006,
which will be subject to FY 2006 fee rates. A second choice is for
applications that will be received on or after October 1, 2006, which
will be subject to FY 2007 fee rates.) After completing data entry,
print a copy of the Medical Device User Fee Cover Sheet and note the
unique Payment Identification Number located in the upper right-hand
corner of the printed cover sheet.
B. Step Two--Electronically Transmit a Copy of the Printed Cover Sheet
with the Payment Identification Number to FDA's Office of Financial
Management
Once you are satisfied that the data on the cover sheet is
accurate, electronically transmit that data to FDA according to
instructions on the screen. Since electronic transmission is possible,
applicants are required to set up a user account and use passwords to
assure data security in the creation and electronic submission of cover
sheets.
[[Page 43786]]
C. Step Three--Mail Payment and a Copy of the Completed Medical Device
User Fee Cover Sheet to the St. Louis Address Specified Below
Make the payment in U.S. currency by check, bank draft, or
U.S. Postal money order payable to the Food and Drug Administration.
(The tax identification number of the Food and Drug Administration is
53-0196965, should your accounting department need this information.)
Please write your application's unique Payment
Identification Number, from the upper right-hand corner of your
completed Medical Device User Fee Cover Sheet, on your check, bank
draft, or U.S. Postal money order.
Mail the payment and a copy of the completed Medical
Device User Fee Cover Sheet to: Food and Drug Administration, P.O. Box
956733, St. Louis, MO, 63195-6733.
If you prefer to send a check by a courier (such as FEDEX, DHL,
UPS, etc.), the courier may deliver the check to: US Bank, Attn:
Government Lockbox 956733, 1005 Convention Plaza, St. Louis, Missouri
63101.
(Note: This address is for courier delivery only. Contact the US
Bank at 314-418-4821 if you have any questions concerning courier
delivery.)
It is helpful if the fee arrives at the bank at least 1 day before
the application arrives at FDA. FDA records the official application
receipt date as the later of the following:
The date the application was received by FDA.
The date US Bank receives the payment. US Bank is required
to notify FDA within 1 working day, using the Payment Identification
Number described previously.
D. Step Four--Submit your Application to FDA with a Copy of the
Completed Medical Device User Fee Cover Sheet
Please submit your application and a copy of the completed Medical
Device User Fee Cover Sheet to one of the following addresses:
Medical device applications should be submitted to: Food
and Drug Administration, Center for Devices and Radiological Health,
Document Mail Center (HFZ-401), 9200 Corporate Blvd., Rockville, MD
20850.
Biologic applications should be sent to: Food and Drug
Administration, Center for Biologics Evaluation and Research, Document
Control Center (HFM-99), suite 200N, 1401 Rockville Pike, Rockville,
Maryland 20852-1448.
Dated: July 26, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-12394 Filed 8-1-06; 8:45 am]
BILLING CODE 4160-01-S